Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

Some studies have suggested that women with metastatic malignant melanoma have a better survival rate than men. However, little is known about the effect of gender on survival in combination with other clinical variables and treatment variables. Thus, an analysis of 813 eligible patients from 15 consecutive Southwest Oncology Group (SWOG) Phase II or III trials evaluating chemotherapy or chemoimmunotherapy for metastatic melanoma was performed.

[1]  Martin F. Mihm,et al.  A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.

[2]  V. Sondak,et al.  Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. , 1998, American journal of clinical oncology.

[3]  V. Sondak,et al.  Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study , 1998, Journal of immunotherapy.

[4]  Q. Dong,et al.  Prognostic factors for survival of patients treated systemically for disseminated melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  V. Sondak,et al.  Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. Sondak,et al.  Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. , 1997, American journal of clinical oncology.

[7]  C. Garbe,et al.  Prolonged survival of 2 years or longer for patients with disseminated melanoma , 1997, Cancer.

[8]  L. Nathanson,et al.  Prognosis and staging in melanoma. , 1996, Seminars in oncology.

[9]  V. Sondak,et al.  The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). , 1996, American journal of clinical oncology.

[10]  D. Morton,et al.  Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.

[11]  V. Sondak,et al.  Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. , 1994, Anti-cancer drugs.

[12]  R. Elashoff,et al.  Application of multistage markov modeling to malignant melanoma progression , 1994, Cancer.

[13]  D. Bajorin,et al.  Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis , 1993, Cancer.

[14]  V. Sondak,et al.  Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma: A Southwest Oncology Group Study , 1993, American journal of clinical oncology.

[15]  E. Borden,et al.  Prognostic factors in metastatic melanoma , 1993, Cancer.

[16]  V. Sondak,et al.  Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial. , 1992, Journal of the National Cancer Institute.

[17]  E. Hersh,et al.  Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. , 1991, Journal of the National Cancer Institute.

[18]  K. Heimdal,et al.  Regression analyses of prognostic factors in metastatic malignant melanoma. , 1989, European journal of cancer & clinical oncology.

[19]  S. Balcerzak,et al.  Phase II evaluation of spirogermanium in malignant melanoma: a Southwest Oncology Group Study. , 1987, Cancer treatment reports.

[20]  C. Balch,et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Bartolucci,et al.  Prognostic factors in metastatic malignant melanoma. The southeastern cancer study group experience , 1982, Cancer.

[22]  F. Rampen.  Malignant melanoma: sex differences in survival after evidence of distant metastasis. , 1980, British Journal of Cancer.

[23]  J. Mulder,et al.  MALIGNANT MELANOMA: AN ANDROGEN-DEPENDENT TUMOUR? , 1980, The Lancet.

[24]  V. Vaitkevicius,et al.  Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. , 1979, Surgery, gynecology & obstetrics.

[25]  L. Einhorn,et al.  Metastatic patterns of choroidal melanoma , 1974, Cancer.

[26]  L. Einhorn,et al.  Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. , 1974, Cancer research.

[27]  O. James,et al.  PAIN IN GASTRIC ULCER , 1974 .

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  V. Sondak,et al.  A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. , 1999, The cancer journal from Scientific American.

[30]  V. Sondak,et al.  A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. , 1995, Investigational new drugs.

[31]  D. Alberts,et al.  Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study. , 1987, Investigational new drugs.

[32]  D.,et al.  Regression Models and Life-Tables , 2022 .